Neoadjuvant Chemotherapy in Resectable Biliary Tract Cancer: A Systematic Review and Metanalysis.
[BACKGROUND AND OBJECTIVES] The benefit of neoadjuvant chemotherapy in resectable biliary tract cancer remains unclear.
- 표본수 (n) 11,344
- OR 1.30
- HR 0.69
- 연구 설계 systematic review
APA
Pereira RA, Barcellos G, et al. (2026). Neoadjuvant Chemotherapy in Resectable Biliary Tract Cancer: A Systematic Review and Metanalysis.. Journal of surgical oncology, 133(3), 313-325. https://doi.org/10.1002/jso.70169
MLA
Pereira RA, et al.. "Neoadjuvant Chemotherapy in Resectable Biliary Tract Cancer: A Systematic Review and Metanalysis.." Journal of surgical oncology, vol. 133, no. 3, 2026, pp. 313-325.
PMID
41424434
Abstract
[BACKGROUND AND OBJECTIVES] The benefit of neoadjuvant chemotherapy in resectable biliary tract cancer remains unclear.
[METHODS] A systematic review and meta-analysis of 23 studies (n = 11,344) compared neoadjuvant chemotherapy with upfront surgery.
[RESULTS] Neoadjuvant therapy improved overall survival (HR = 0.69) and R0 resection rates (OR = 1.30) without increasing postoperative morbidity or mortality.
[CONCLUSIONS] Neoadjuvant chemotherapy may improve survival and surgical outcomes in resectable biliary tract cancer.
[METHODS] A systematic review and meta-analysis of 23 studies (n = 11,344) compared neoadjuvant chemotherapy with upfront surgery.
[RESULTS] Neoadjuvant therapy improved overall survival (HR = 0.69) and R0 resection rates (OR = 1.30) without increasing postoperative morbidity or mortality.
[CONCLUSIONS] Neoadjuvant chemotherapy may improve survival and surgical outcomes in resectable biliary tract cancer.
MeSH Terms
Humans; Neoadjuvant Therapy; Biliary Tract Neoplasms; Chemotherapy, Adjuvant